Navigation Links
Mirati Therapeutics Reports Third Quarter 2013 Financial Results
Date:11/12/2013

of 2014. We will complete discussions with the FDA to finalize our SPA for the design of a Phase 3 registration trial for mocetinostat in patients with myelodysplastic syndrome. This trial could be started by the second half of 2014."

Third Quarter and Nine Months Ended September 30, 2013 Financial Results Cash, cash equivalents, marketable securities and restricted cash totaled $15.3 million as of September 30, 2013 compared to $37.3 million on December 31, 2012. The cash does not include the $53.0 million in net proceeds from the public offering of 3.25 million shares of the Company's common stock, which closed on October 29, 2013. The Company believes that with the recent financing it has sufficient financial resources to carry forward its current clinical development and operating plans through the end of 2015.

Net research and development expenditures for the third quarter of 2013 were $5.5 million, $1.2 million higher than the third quarter of 2012. The higher expenses primarily reflect increased costs for mocetinostat and MGCD516. Net research and development expenditures were $15.5 million for the first nine months of 2013, compared to $10.1 million for the same period in 2012. Increases were primarily due to the factors listed above as well as increased costs for MGCD265, costs associated with organizational changes implemented in 2013 and a reduction in investment tax credits versus the prior year.

General and administrative expenses in the third quarter of 2013 were $3.7 million, $2.0 million higher than in the third quarter of 2012. General and administrative expenses were $8.6 million in the first nine months, compared to $4.0 million for the same period in 2012. The increase primarily reflects higher share-based compensation costs and costs associated with the recent corporate reorganization and associated management changes.

Other expense, net in the third quarter of 2013 was $20.1 million compared to other income, net of
'/>"/>

SOURCE Mirati Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Mirati Therapeutics Prices Public Offering Of Common Stock
2. Sorrento Therapeutics Adopts Stockholder Rights Plan
3. Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
4. Shield Therapeutics Files Investigational New Drug Application for ST10 for the Treatment of Iron Deficiency in Chronic Kidney Disease
5. Cara Therapeutics Files Registration Statement for Proposed Initial Public Offering
6. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
7. Echo Therapeutics Announces Third Quarter 2013 Financial Results
8. Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference
9. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
10. PDL BioPharma Provides $70 Million in Financing to Durata Therapeutics
11. PTC Therapeutics to Present at Credit Suisse Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH ... President and Chief Executive Officer, will present a corporate ... Anthera will present at 4:30PM ET, ... New York City . ... a biopharmaceutical company focused on developing and commercializing products ...
(Date:11/22/2014)... Nov. 21, 2014  CytoSorbents Corporation (OTCQB: CTSO), ... Union approved CytoSorb® cytokine adsorber to treat critically-ill ... Beacon of Light Award at last night,s New ... Dr. Phillip Chan , Chief Executive ... to be recognized by the New Jersey Tech ...
(Date:11/22/2014)... -- MEDITE Group acquired by CytoCore, Inc. (OTCBB: CYOE) on ... quarter sales ended September 30, 2014 of $8.7 million ... months ended September 2014 and a $38,000 loss for the ... quarter is usually a seasonable weak period due to the ... many countries worldwide, we are proud to announce record sales ...
Breaking Medicine Technology:Anthera Pharmaceuticals to Present at Annual Piper Jaffray Healthcare Conference 2CytoSorbents Wins Beacon of Light Award 2CytoSorbents Wins Beacon of Light Award 3CytoSorbents Wins Beacon of Light Award 4CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 2CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 3
... /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: ... specializes in patented biopharmaceutical medicine, modernized traditional Chinese ... its corporate business & development information on OneMedDatabase, ... research and business & development firm. ...
... April 4, 2011 OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... their pipeline compound OGX-427 was presented at the AACR ... of OGX-427 to inhibit Heat Shock Protein 27 (Hsp27), ... in the proliferation of castrate resistant prostate cancer (CRPC) ...
Cached Medicine Technology:TPI Business and Development Profile Updated on OneMedDatabase 2TPI Business and Development Profile Updated on OneMedDatabase 3OncoGenex Announces Data Highlighting OGX-427 at American Association of Cancer Research (AACR) 102nd Annual Meeting 2011 2OncoGenex Announces Data Highlighting OGX-427 at American Association of Cancer Research (AACR) 102nd Annual Meeting 2011 3
(Date:11/23/2014)... November 24, 2014 iFitDress.com, a well-known wedding ... black evening gowns . They are now offered at ... offer will last from now to Dec. 15. The main ... , All the company’s high quality items are ideal options ... a large sum of money. All its new mint cocktail ...
(Date:11/23/2014)... Tbdress.com has recently announced that its Special Friday ... The special offer will provide ladies many gorgeous shoes at ... world’s largest women’s dresses retailers, and its shoes include many ... discounts on that day: Everything at Tbdress.com is up to ... $89). , People can use the following coupon codes as ...
(Date:11/23/2014)... FRIDAY, Nov. 21, 2014 (HealthDay News) -- Close friends ... general peer group does, a new study says. ... and peers have an influence on individual alcohol use, ... the broader peer group and the friend group,s influence ... Indiana University,s School of Public Health, said in a ...
(Date:11/23/2014)... 23, 2014 This evaluation provides ... its significance, programs and manufacturing technological innovation. Then, ... major market gamers in information. In this part, ... prospective, manufacturing value, and 2009-2014 market shares for ... symbolizes the globally and Chinese suppliers finish market ...
(Date:11/23/2014)... More than two dozen new claims were ... involving Byetta lawsuits ( http://www.byettalawsuit2013.com/ ), as well as ... , A Case List updated on November 17th ... 2 diabetes medications referred to as incretin mimetics have ... District of California, where a federal proceeding continues to ...
Breaking Medicine News(10 mins):Health News:Trendy Long Black Evening Gowns Now Provided By iFitDress.com 2Health News:Tbdress.com Special Friday Shoes Sales Online Now 2Health News:Close Friends May Be Key to Teens' Drinking 2Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 2Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 3Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 4Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 3Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 4
... , BOULDER, Colo., Dec. 25 elepha ... AD IN YOGA JOURNAL MAGAZINE: EFFECTIVE ADVERTISING , Lululemon, the successful yoga ... park. It,s the kind of ad that earns its maker internet buzz, ... ad, featuring a disabled yogini, visit elephantjournal.com: , http://www.eleph ...
... while sticking to your diet. Here,s how. , FRIDAY, Dec. 25 ... you,ve eaten and that box of Santa Claus-shaped candies is calling ... overeat and overindulge aren,t over yet. , Before you take one ... to get a handle on your holiday eating. , If you,ve ...
... promise for humans with hereditary disease , THURSDAY, Dec. ... discovered a molecular switch that appears to play a ... An estimated one out of every 10,000 Americans suffer ... person,s ability to walk, talk, think clearly and even ...
... , PHILADELPHIA, Dec. 24 Congressman Chaka Fattah (D-PA) releases ... healthcare reform legislation: , "Senate Democrats deserve our thanks ... work to do, but I am confident that the House ... in the new year we will be sending President Obama ...
... Today,s passage of health care reform in the U.S. Senate ... a promise we will make to every person living in this ... will be able to afford coverage and insurance companies will not ... other steps will include final passage after conference committee, effective implementation ...
... Idaho Says Now Is the Time for State Congressional Delegation to ... Before the sun was up in Idaho this morning, ... a glimmer of hope from Washington, D.C. With the Senate ... congressional delegation can play a key role in making the bill ...
Cached Medicine News:Health News:Waylon Lewis of elephantjournal.com: Lululemon Ad; Naropa University Budget 2Health News:Eat Up, But Eat Healthy This Holiday Season 2Health News:Scientists Find Molecular Switch Related to Huntington's 2Health News:A Promise to Keep. Senate Vote is the First Step Toward the Promise of Quality, Affordable Health Care for All 2Health News:Health Care Reform Moves One Step Closer to Bringing Relief to Idaho Families 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: